Drug-Induced Acute Interstitial Nephritis: Diagnosis & Care (ICD-10 Code: N14.1_5)

Medical Disclaimer

This condition guide is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding any symptoms or medical conditions.

Clinical Assessment & Protocol

Typical Presentation (HPI)

EN: Patient presents with acute kidney injury (AKI) following recent initiation of [Medication Name]. Symptoms include [oliguria/polyuria], flank pain, and systemic manifestations including [fever/rash/arthralgia]. No history of recent hypotension, nephrotoxin exposure, or obstructive uropathy. AR: يراجع المريض بقصور كلوي حاد (AKI) بعد البدء مؤخراً بتناول [اسم الدواء]. تشمل الأعراض [قلة البول/كثرة البول]، ألم في الخاصرة، ومظاهر جهازية تشمل [حمى/طفح جلدي/ألم مفصلي]. لا يوجد تاريخ حديث لانخفاض ضغط الدم، أو التعرض لسموم كلوية، أو اعتلال بولي انسدادي.

General Examination

EN: Vitals: [Temp/BP/HR]. General: Patient appears [well/ill]-appearing. Skin: Presence of maculopapular rash on [location]. HEENT: No mucosal involvement. Lymphatics: No generalized lymphadenopathy. AR: العلامات الحيوية: [درجة الحرارة/ضغط الدم/معدل ضربات القلب]. الحالة العامة: المريض يبدو [بحالة جيدة/مريضاً]. الجلد: وجود طفح جلدي بقعي مسطح في [الموقع]. الرأس والعنق: لا يوجد إصابة في الأغشية المخاطية. الجهاز اللمفاوي: لا يوجد ضخامة عقد لمفاوية معممة.

Treatment Protocol

EN: 1. Immediate discontinuation of offending agent: [Medication Name]. 2. Supportive care with IV fluid resuscitation if volume depleted. 3. Consider short-course systemic corticosteroids (e.g., Prednisone 0.5-1 mg/kg/day) if renal function does not improve upon drug withdrawal. 4. Monitor serial serum creatinine and urine output. AR: 1. التوقف الفوري عن تناول الدواء المسبب: [اسم الدواء]. 2. الرعاية الداعمة مع تعويض السوائل الوريدية في حال وجود نقص حجم. 3. النظر في استخدام دورة قصيرة من الكورتيكوستيرويدات الجهازية (مثل بريدنيزون 0.5-1 ملغ/كغ/يوم) إذا لم تتحسن الوظيفة الكلوية بعد سحب الدواء. 4. مراقبة الكرياتينين في المصل وحجم البول بشكل دوري.

Patient Education

EN: You have been diagnosed with drug-induced kidney inflammation. It is critical to stop the identified medication immediately and avoid it permanently. Provide a list of all medications, including over-the-counter drugs and supplements, to your healthcare provider. Seek immediate care if you develop decreased urine output, swelling, or fever. AR: تم تشخيصك بالتهاب كلوي ناتج عن دواء. من الضروري جداً التوقف فوراً عن تناول الدواء المحدد وتجنبه بشكل دائم. قدم قائمة بجميع الأدوية التي تتناولها، بما في ذلك الأدوية التي لا تستلزم وصفة طبية والمكملات الغذائية، لمقدم الرعاية الصحية الخاص بك. اطلب الرعاية الطبية الفورية إذا لاحظت انخفاضاً في كمية البول، أو تورماً، أو حمى.

Systemic & Specialized Examinations

Cardiovascular

EN: Heart: Regular rate and rhythm. S1/S2 present. No murmurs, rubs, or gallops. Peripheral pulses symmetric. No peripheral edema noted. AR: القلب: النظم والسرعة منتظمان. الأصوات القلبية S1/S2 مسموعة. لا يوجد نفخات، احتكاكات، أو أصوات إضافية. النبضات المحيطية متناظرة. لا يوجد وذمة محيطية.

Gastrointestinal

EN: Abdomen: Soft, non-tender, non-distended. Bowel sounds present. No hepatosplenomegaly or palpable masses. AR: البطن: طري، غير مؤلم عند الجس، غير متطبلل. أصوات الأمعاء مسموعة. لا يوجد ضخامة كبدية طحالية أو كتل محسوسة.

1. Executive Overview: Understanding Drug-Induced AIN

Acute Interstitial Nephritis (AIN), specifically the drug-induced subtype (ICD-10: N14.1_5), represents a critical subset of acute kidney injury (AKI). Unlike glomerular diseases, which primarily affect the filtering apparatus of the kidney, AIN is characterized by an acute inflammatory process within the renal interstitium and the renal tubules.

Drug-induced AIN is an idiosyncratic hypersensitivity reaction that occurs when the kidneys are exposed to specific pharmaceutical agents. It is responsible for approximately 15% to 27% of cases of unexplained acute renal failure in hospitalized patients. As a clinical entity, it requires prompt identification and withdrawal of the offending agent to prevent the progression from reversible acute tubular injury to irreversible interstitial fibrosis and chronic kidney disease (CKD).

2. Pathophysiology, Etiology, and Risk Factors

The Mechanisms of Injury

Drug-induced AIN is largely a Type IV (delayed-type) hypersensitivity reaction. The offending drug acts as a hapten, binding to tubular basement membrane proteins. This complex is then presented to T-lymphocytes, triggering a cell-mediated immune response.

Glomerular vs. Tubular Pathology: While glomerular diseases often present with hematuria, proteinuria, and hypertension, AIN is fundamentally a tubular-interstitial process. The inflammation primarily involves the interstitium, causing edema and leukocyte infiltration (T-cells, macrophages, and eosinophils).
Cellular Consequences: As the interstitium becomes inflamed, tubular epithelial cells undergo stress, leading to decreased reabsorption of solutes and impaired concentration ability, often manifesting as polyuria or electrolyte wasting.

Common Etiological Agents

A vast array of medications can induce AIN. The most common offenders include:
* Antibiotics: Penicillins, cephalosporins, sulfonamides, and fluoroquinolones.
* Proton Pump Inhibitors (PPIs): Omeprazole, lansoprazole (highly common in outpatient settings).
* NSAIDs: Ibuprofen, naproxen (often associated with minimal change disease/nephrotic syndrome as well).
* Anticonvulsants: Phenytoin and carbamazepine.
* Diuretics: Thiazides and furosemide.

Risk Factors

Polypharmacy: Patients on multiple medications have a statistically higher risk of idiosyncratic reactions.
Age: Elderly patients are at higher risk due to reduced renal reserve and altered drug metabolism.
Pre-existing CKD: Underlying renal impairment lowers the threshold for further injury.

3. Signs, Symptoms, and Clinical Presentation

The classic triad of "fever, rash, and eosinophilia" is observed in fewer than 10% of cases. Clinicians must maintain a high index of suspicion based on biochemical trends.

Clinical Manifestations

Asymptomatic AKI: Many patients present solely with an unexplained rise in serum creatinine.
Uremic Symptoms: Nausea, vomiting, fatigue, and altered mental status as the GFR drops precipitously.
Fluid and Electrolyte Imbalance: Hypertension, peripheral edema, or, conversely, polyuria due to tubular dysfunction.
Systemic Consequences: If left untreated, the inflammatory process leads to systemic uremia, which can affect cardiovascular, hematological, and neurological systems.

Nephrotic vs. Nephritic Presentations

Feature	Nephritic (AIN/Glomerulonephritis)	Nephrotic Syndrome
Proteinuria	Sub-nephrotic (<3g/day)	Nephrotic range (>3.5g/day)
Hematuria	Often present (RBC casts)	Rare
Blood Pressure	Usually elevated	Can be normal
Primary Site	Interstitium/Tubules	Glomerular basement membrane

4. Diagnostic Evaluation and Workup

The diagnosis of drug-induced AIN is often one of exclusion and clinical association.

Laboratory Assays

Serum Creatinine and eGFR: KDIGO guidelines define AKI by a 0.3 mg/dL rise in creatinine within 48 hours or a 1.5x increase from baseline.
Urinalysis: Look for sterile pyuria (white blood cells in urine without infection) and eosinophiluria (though the sensitivity/specificity of Hansel’s stain for eosinophiluria is debated).
Proteinuria Profile: Typically tubular proteinuria (low molecular weight proteins) rather than albuminuria.

Imaging and Biopsy

Renal Ultrasound: Essential to rule out post-renal obstruction (hydronephrosis) and to assess renal size. In AIN, kidneys often appear enlarged and hyperechoic due to interstitial edema.
Renal Biopsy: The gold standard. Indications include:
- Failure to recover renal function after 3–5 days of drug withdrawal.
- Unclear etiology of AKI.
- Need to differentiate AIN from acute tubular necrosis (ATN) or rapidly progressive glomerulonephritis (RPGN).

5. Therapeutic Interventions

Pharmacotherapy

Immediate Cessation: The primary treatment is the prompt identification and discontinuation of the offending drug.
Corticosteroids: While controversial, many specialists utilize a short course of high-dose corticosteroids (e.g., prednisone 0.5–1.0 mg/kg/day) to dampen the inflammatory interstitial response, especially if biopsy confirms significant interstitial infiltrate.
Supportive Care: Management of fluid balance, electrolyte disturbances (hyperkalemia, acidosis), and potential need for short-term Renal Replacement Therapy (RRT/Dialysis) if the patient develops refractory uremia.

Lifestyle and Long-term Management

Avoidance: Permanently avoid the offending drug and classes of drugs that exhibit cross-reactivity.
Monitoring: Regular follow-up of serum creatinine and urine protein-to-creatinine ratios to ensure the return to baseline renal function.
CKD-MBD Management: If the kidney injury transitions into CKD, monitor Calcium, Phosphate, and Parathyroid Hormone (PTH) levels to prevent metabolic bone disease.

6. Frequently Asked Questions (FAQ)

1. Can AIN be cured completely?
Yes, if the offending medication is identified and removed early, many patients recover renal function. However, delayed diagnosis can lead to permanent interstitial fibrosis.

2. How long does it take for kidneys to recover after stopping the drug?
Recovery usually begins within a few days to weeks of drug cessation. If no improvement is seen within two weeks, biopsy is mandatory.

3. Is a renal biopsy dangerous?
A biopsy is a minor surgical procedure performed by a specialist. While it carries small risks of bleeding, it is the only way to definitively diagnose AIN and determine the degree of fibrosis.

4. Why is eosinophiluria not always reliable?
While eosinophils in the urine suggest AIN, the sensitivity and specificity of the test are low. A negative result does not rule out AIN.

5. Are PPIs really a common cause of AIN?
Yes, Proton Pump Inhibitors (like omeprazole) are a leading cause of drug-induced AIN in modern clinical practice, often causing a silent, insidious decline in GFR.

6. Does AIN always lead to chronic kidney disease?
Not always, but repetitive episodes of AIN or prolonged untreated inflammation can lead to permanent scarring of the kidney tissue, resulting in CKD.

7. Should I stop all my medications if I suspect AIN?
No. Only a physician can safely evaluate which medication is the likely culprit. Stopping necessary life-saving medications without supervision can be dangerous.

8. What is the role of steroids in AIN?
Steroids are used to suppress the immune system's attack on the kidneys. They are generally reserved for cases where renal function does not improve after stopping the drug.

9. Can AIN be diagnosed with blood tests alone?
No. Blood tests show that the kidneys are failing, but they cannot distinguish between AIN, ATN, or glomerular disease. Biopsy remains the definitive diagnostic tool.

10. How do I prevent AIN in the future?
Always maintain an updated list of your medications, including over-the-counter supplements and NSAIDs, and inform your nephrologist about all past adverse drug reactions.